Moreover, we demonstrated that in NSCLC patients treated with nivolumab, the soluble PD1 decreased after therapy in responder patients, while non-responders showed increasing levels of the soluble LAG3 [19]. The gene discussed is LAG3; the disease is non-small cell lung carcinoma.